Adverse events by group
| Add-on (n=49) | Switch (n=53) | |||
| AE | SAE | AE | SAE | |
| Infections and infestations | 4, 8.2% | 1, 2.0% | 8, 14.8% | 0 |
| Gastrointestinal disorders | 9, 18.4% | 0 | 0 | 0 |
| Hepatobiliary disorders | 3, 6.1% | 0 | 2, 3.7% | 0 |
| Respiratory, thoracic and mediastinal disorders | 4, 8.2% | 0 | 0 | 0 |
| Laboratory test abnormalities | 2, 4.1% | 0 | 0 | 0 |
| Metabolism and nutrition disorders | 3, 6.1% | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | 2, 4.1% | 0 | 2, 3.7% | 0 |
| Injury, poisoning and procedural complications | 3, 6.1% | 0 | 1, 1.9% | 0 |
| General disorders and administration site conditions | 1, 2.0% | 0 | 0 | 0 |
| Neoplasms benign, malignant, unspecified | 1, 2.0% | 1, 2.0% | 3, 5.6% | 0 |
| Eye disorders | 1, 2.0% | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | 1, 2.0% | 0 | 0 | 0 |
| Blood and lymphatic system disorders | 1, 2.0% | 0 | 0 | 0 |
Values are presented as N, %.
AE, adverse event; SAE, serious adverse event.